9 results about "Cell Proliferation Process" patented technology

The invention provides a KIF18 inhibitor and a synthesis method thereof, and particularly provides a compound shown as a formula (I), and the compound can regulate KIF18A protein, so that the cell cycle and the cell proliferation process are influenced to treat cancers and cancer-related diseases. Also provided are pharmaceutical compositions comprising the compounds and methods for treating conditions associated with KIF18A activity.

The invention relates to a KIF18 inhibitor with a structure as shown in a formula (I) and a synthesis method thereof, and the compound can regulate KIF18A protein so as to influence a cell cycle and a cell proliferation process to treat cancers and cancer-related diseases. And pharmaceutical compositions comprising the compounds, methods for treating conditions associated with KIF18A activity.

This invention discloses a cell proliferation culture device, belonging to the field of biomedical experimental equipment technology, comprising: a culture body, a microporous membrane, a microfluidic channel, a temperature control module, a sensor module, a sampler, and a control unit. The cell proliferation culture device of this invention can dynamically monitor the glucose consumption rate and lactate production rate during cell proliferation in real time, supports pollution-free dynamic sampling and rapid microenvironment switching, and is particularly suitable for studying the interaction between SIRT2 and HKII to regulate aerobic glycolysis and growth proliferation of colorectal cancer cells. It also has advantages such as real-time monitoring, high sensitivity, pollution-free sampling, and dynamic microenvironment control.

The invention relates to a KIF18 inhibitor and a synthesis method thereof, and the KIF18 inhibitor can regulate KIF18A protein so as to influence the cell cycle and the cell proliferation process to treat cancers and cancer-related diseases. Also included are pharmaceutical compositions comprising the KIF18 inhibitor compounds and methods for treating conditions associated with KIF18A activity.

Provided in the present application is a compound as represented by formula (1). The compound can regulate the KIF18A protein, thereby affecting the cell cycle and the cell proliferation process to treat cancer and cancer-associated diseases. The present disclosure further comprises a pharmaceutical composition containing the compound, and a method for treating conditions associated with the KIF18A activity.

A method for removing solute while retaining suspended cells in a bioreactor comprises the steps of positioning the cell suspension within a designated area of ​​the bioreactor and generating a flow rate in the suspension within the bioreactor, the flow rate being selected such that the cells are retained in the bioreactor while the solute exits the bioreactor.

Compounds of formula (I):as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

The present application provides a compound represented by formula (I), which can affect cell cycle and cell proliferation processes to treat cancer and cancer-related diseases by regulating KIF18A protein. The present invention further includes pharmaceutical compositions containing the compounds and methods for treating pathologies associated with KIF18A activity. [Formula 1] TIFF2026508745000671.tif39170

The invention belongs to the technical field of food deep processing, and provides a method for solid-state fermentation of tartary buckwheat with high yield of triterpenoid active components by using morchella. The preparation method comprises the following steps: inoculating a morchella fermentation liquid into sterilized tartary buckwheat, carrying out constant-temperature fermentation culture at 24-30 DEG C for 15-25 days, and drying at 60 DEG C for 18 hours, so as to obtain the morchella solid-state fermented tartary buckwheat with high yield of triterpenoid active ingredients, the sterilized tartary buckwheat is prepared by the following steps: soaking 50g of tartary buckwheat in purified water with the volume 4 times that of the tartary buckwheat for 24 hours, draining, and sterilizing for 1 hour by high-pressure steam at 121 DEG C; the inoculum size of the morchella fermentation liquor is 3-7 mL. The four triterpenoid components are analyzed by using non-targeted metabonomics, the four triterpenoid components are all in an up-regulation trend in a tartary buckwheat solid-state fermentation process by using morchella, the up-regulation trend of beta-citraulin and ganoderic acid is most obvious, and relative quantitative values are respectively up-regulated by 404.44% and 195.42% when the tartary buckwheat is fermented for 20 days; in addition, the two triterpenoid components are important intermediates in the fungal cell proliferation process, and up-regulation of response values of the two triterpenoid components also reflects continuous proliferation of fungal cells in the fermentation process.